The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study

Barreira, Sofia; Fonseca, João Eurico

doi:10.1007/s12016-016-8547-6

Cited by 15 publications

(5 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of MTX on fragility fractures is still controversial. Though some studies have indicated that MTX has a positive impact on bone metabolism and bone mineral density (BMD) stabilization in RA patients, additional studies are required to determine whether this effect is sufficient to reduce their risk of fractures [ 41 , 45 ]. As for the risk of malignancies, existing evidence is insufficient to make a full assessment [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

Jin

Fang³

et al. 2017

Arthritis Res Ther

View full text Add to dashboard Cite

Background: Rheumatoid arthritis patients are at higher risk of developing comorbidities. The main objective of this study was to evaluate the prevalence of major comorbidities in Chinese rheumatoid arthritis patients. We also aimed to identify factors associated with these comorbidities. Methods: Baseline demographic, clinical characteristics and comorbidity data from RA patients enrolled in the Chinese Registry of rhEumatoiD arthrITis (CREDIT) from Nov 2016 to August 2017 were presented and compared with those from five other registries across the world. Possible factors related to three major comorbidities (cardiovascular disease, fragility fracture and malignancy) were identified using multivariate logistic regression analyses. Results: A total of 13,210 RA patients were included (80.6% female, mean age 52.9 years and median RA duration 4.0 years). Baseline prevalence rates of major comorbidities were calculated: CVD, 2.2% (95% CI 2.0-2.5%); fragility fracture, 1.7% (95% CI 1.5-1.9%); malignancy, 0.6% (95% CI 0.5-0.7%); overall major comorbidities, 4.2% (95% CI 3.9-4.6%). Advanced age was associated with all comorbidities. Male gender and disease duration were positively related to CVD. Female sex and longer disease duration were potential risk factors for fragility fractures. Ever use of methotrexate (MTX) was negatively related to baseline comorbidities. Conclusions: Patients with rheumatoid arthritis in China have similar prevalence of comorbidities with other Asian countries. Advanced age and long disease duration are possible risk factors for comorbidities. On the contrary, MTX may protect RA patients from several major comorbidities, supporting its central role in the management of rheumatoid arthritis.

show abstract

Section: Discussionmentioning

confidence: 99%

Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

Jin

Fang³

et al. 2017

Arthritis Res Ther

View full text Add to dashboard Cite

show abstract

“…Several studies have explored the efficacy of conventional disease modifying anti-rheumatic drugs (DMARDs) in the prevention of bone loss in RA patients, with controversial results [62]. Overall, studies have found a possible small positive effect on bone density and metabolism, probably mediated by the reduction of inflammation [63]. Some controversy also still remains regarding biological DMARDs and OP prevention in RA [64,65,66].…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

Osteoporosis in Rheumatic Diseases

Adami

Fassio

Rossini

et al. 2019

IJMS

View full text Add to dashboard Cite

Osteoporosis is a chronic disease characterized by an increased risk of fragility fracture. Patients affected by rheumatic diseases are at greater risk of developing osteoporosis. The purpose of the present review is to discuss the pathogenesis, epidemiology, and treatment of osteoporosis in patients affected by rheumatic diseases with special focus for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, vasculitides, Sjogren syndrome, and crystal-induced arthritis.

show abstract

“…Mounting evidence has revealed a connection between bone metabolism and immune-mediated inflammatory diseases 12,13 . According to an epidemiological survey, RA induces low bone turnover, resulting in a twofold increase in the incidence of osteoporosis (OP) and a 1.35–2.13-fold increase in the fragility fracture risk 12,14 . A variety of inflammatory cytokines were recently found to affect the osteogenic differentiation of stem cells 15–18 .…”

Section: Introductionmentioning

confidence: 99%

Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway

Zhang

Hang

et al. 2019

Cell Death Dis

View full text Add to dashboard Cite

Interleukin (IL)-37, a pivotal anti-inflammatory cytokine and a fundamental inhibitor of innate immunity, has recently been shown to be abnormally expressed in several autoimmune-related orthopedic diseases, including rheumatoid arthritis, ankylosing spondylitis, and osteoporosis. However, the role of IL-37 during osteogenic differentiation of mesenchymal stem cells (MSCs) remains largely unknown. In this study, extracellular IL-37 significantly increased osteoblast-specific gene expression, the number of mineral deposits, and alkaline phosphatase activity of MSCs. Moreover, a signaling pathway was activated in the presence of IL-37. The enhanced osteogenic differentiation of MSCs due to supplementation of IL-37 was partially rescued by the presence of a PI3K/AKT signaling inhibitor. Using a rat calvarial bone defect model, IL-37 significantly improved bone healing. Collectively, these findings indicate that extracellular IL-37 enhanced osteogenesis of MSCs, at least in part by activation of the PI3K/AKT signaling pathway.

show abstract

The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study

Cited by 15 publications

References 68 publications

Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

Osteoporosis in Rheumatic Diseases

Extracellular IL-37 promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via activation of the PI3K/AKT signaling pathway

Contact Info

Product

Resources

About